NCT04965519View on ClinicalTrials.gov

A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies

PHASE2RecruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

December 21, 2021

Primary Completion Date

October 31, 2024

Study Completion Date

June 30, 2025

Conditions

Gynecological Malignancy

Interventions

DRUG

RC48-ADC

2.0mg/kg IV every 2 weeks

Trial Locations (1)

100021

RECRUITING

Chinese Academy of Medical Sciences Cancer Hospital, Beijing

All Listed Sponsors

lead

RemeGen Co., Ltd.

INDUSTRY